Concepedia

Author

Sumiko Okubo

Kawasaki Medical School

Also Known As

S Okubo, S. Okubo, Shu Okubo, Sumiko OKUBO, Sumiko Okubo

39

Publications

400

Citations

11

H-Index

12

Concepts

All Affiliations

Kawasaki Medical SchoolABB (Japan)AbbVie (United States)AbbVie (Japan)Tokyo National Hospital
SO

About

Sumiko Okubo is an author at Kawasaki Medical School specializing in oncology, medicine, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

105

2

Pathology

2

2

51

3

Cell Biology

1

1

54

4

Immunology

1

1

20

5

Pharmacology

1

1

31

Sumiko Okubo

×

10

Publications

316

Citations

10

H-Index

YearCitations

Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells

Sumiko Okubo, Junichi Kurebayashi, Takemi Otsuki,

British Journal of Cancer

2004

68

Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells

Junichi Kurebayashi, Sumiko Okubo, Yutaka Yamamoto,

Cancer Chemotherapy and Pharmacology

2006

54

Loss of BRCA1 expression may predict shorter time-to-progression in metastatic breast cancer patients treated with taxanes.

Junichi Kurebayashi, Yutaka Yamamoto, Masafumi Kurosumi,

PubMed

2006

37

Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer

Hibiki Udagawa, Hiroaki Akamatsu, Kentaro Tanaka,

Lung Cancer

2019

31

Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy

Kazuhito Yamamoto, Atsushi Shinagawa, Courtney D. DiNardo,

Japanese Journal of Clinical Oncology

2021

29

Pemetrexed-related interstitial lung disease reported from post marketing surveillance (malignant pleural mesothelioma/non-small cell lung cancer)

Keisuke Tomii, Terufumi Kato, Masashi Takahashi,

Japanese Journal of Clinical Oncology

2017

28

Combined Measurement of Serum Sialyl Lewis X with Serum CA15-3 in Breast Cancer Patients

Junichi Kurebayashi, Tsunehisa Nomura, Mai Hirono,

Japanese Journal of Clinical Oncology

2006

24

Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma

Koji Izutsu, Kazuhito Yamamoto, Koji Kato,

International Journal of Hematology

2020

20

Establishment of enzyme-linked immunosorbent assays for thymidylate synthase and dihydropyriminide dehydrogenase in cancer tissues

Junichi Kurebayashi, Yutaka Yamamoto, Kiyoshi Udagawa,

Oncology Reports

2004

14

Phase 1 study of telisotuzumab vedotin in Japanese patients with advanced solid tumors

Yutaka Fujiwara, Hirotsugu Kenmotsu, Noboru Yamamoto,

Cancer Medicine

2021

11

Page 1